Latest 10-K annual reports

Plum Acquisition Corp. IV announces a definitive business combination agreement with Controlled Thermal Resources Holdings Inc., aiming to close the merger after shareholder approvals and customary conditions.

CBAK Energy Technology, Inc. reported a net loss of $10.4 million for fiscal year 2025, a significant decline from the prior year's net income, as it navigates product transitions and capacity expansions.

XBP Global Holdings, Inc. reports a significant net profit in 2025 driven by reorganization gains, despite revenue decline and substantial goodwill impairment, as it focuses on AI-driven automation and global expansion.

SS Innovations International, Inc. filed an amendment to its 2025 annual report to include a new executive compensation clawback policy and updated certifications.

Cadiz Inc.'s 2025 annual report details significant progress on its Mojave Groundwater Bank project, record revenue growth for its ATEC Water Systems subsidiary, and ongoing efforts to secure substantial capital for infrastructure development.

DSwiss, Inc. reported a net loss of $76,860 for fiscal year 2025, a significant decline from the previous year's profit, raising substantial doubt about its ability to continue as a going concern.

Cadrenal Therapeutics reports increased losses and a significant cash burn in its 2025 annual report, raising substantial doubt about its ability to continue as a going concern, despite advancing its lead drug candidate CAD-1005 towards a pivotal Phase 3 trial.

Professional Diversity Network, Inc. reported a significant increase in net loss for fiscal year 2025, driven by declining core business revenues and substantial investments in new Web3.0 and digital asset initiatives.

Massimo Group reported a 34.3% revenue decline in 2025 to $71.8 million, driven by strategic inventory de-stocking and macroeconomic pressures, yet achieved significant gross margin expansion to 37.5%.

Canton Strategic Holdings, Inc. has completed a major strategic shift from biotechnology to a digital asset treasury strategy focused on Canton Coin and the Canton Network, raising over $537 million in capital.

TLGY Acquisition Corporation reported a significant net loss for 2025, driven by warrant revaluation, while continuing efforts to finalize its business combination with StablecoinX Assets Inc. by April 2026, despite substantial liquidity challenges and a going concern warning.

ModuLink Inc. reported a significant net loss for 2025, driven by operational expansion and business combination costs, while outlining strategic shifts towards design and project management services and an AI robotics acquisition.

Kartoon Studios, Inc. reported a 21% increase in total revenue to $39.4 million for fiscal year 2025, yet net loss attributable to the company widened to $24.5 million, raising substantial doubt about its ability to continue as a going concern.

Imunon, Inc. announced positive final Phase 2 data for its lead ovarian cancer immunotherapy, IMNN-001, showing significant overall survival benefits, but also disclosed substantial doubt about its ability to continue as a going concern.

SPAR Group, Inc. reported a significant net loss and revenue decline for fiscal year 2025, alongside a Nasdaq delisting notice and executive changes, despite remediating prior internal control weaknesses.

Caring Brands, Inc. reported a substantial net loss of $6.28 million for 2025, despite completing an initial public offering and advancing its wellness product pipeline.

Sow Good Inc. has fundamentally restructured its operations, selling manufacturing assets and transitioning to a commission-based distribution model following significant losses and a decline in the freeze-dried candy market.

Perpetua Resources progresses its Stibnite Gold Project with key federal permits, securing substantial equity and a $2.7 billion U.S. EXIM loan notification, despite ongoing legal challenges and a net loss.

Cocrystal Pharma's annual report highlights significant financial challenges, including a going concern doubt and a failed Phase 2a influenza trial, despite progress in other antiviral programs.

Palvella Therapeutics announced positive Phase 3 clinical trial results for QTORIN rapamycin in microcystic lymphatic malformations and secured $215.8 million in a public offering, despite ongoing operating losses.

1847 Holdings LLC reported a significant turnaround in net income and revenue for 2025, driven by its construction segment, despite auditors issuing a going concern opinion due to substantial liabilities and near-term debt maturities.

Dominari Holdings Inc. announced a significant revenue surge in 2025 driven by its financial services expansion, despite reporting a larger net loss and identifying material weaknesses in internal controls.

AquaBounty Technologies, Inc. has significantly restructured its operations by divesting key assets and pausing its Ohio Farm Project, leading to substantial impairment charges and raising doubts about its ability to continue as a going concern.

AirJoule Technologies Corporation reported a net loss of $9.0 million for 2025, driven by significant impairment charges in its AirJoule JV, despite advancing its water harvesting technology and securing new capital.

LM Funding America, Inc. reported a significantly increased net loss for 2025, driven by decreased Bitcoin mining revenue and impairment losses, while facing a Nasdaq delisting notice.

Galectin Therapeutics reports 2025 annual results, highlighting mixed NAVIGATE trial outcomes for belapectin in MASH cirrhosis and ongoing financing needs.

Latch, Inc., now operating as DOOR, reported a net loss of $53.7 million for 2025, alongside revenue growth and ongoing efforts to remediate material weaknesses in internal controls.

YHN Acquisition I Limited, a SPAC, has extended its business combination deadline to June 19, 2026, and reported a net income of $1.33 million for 2025, while facing going concern doubts.

BT Brands reported improved net loss and EBITDA in fiscal 2025 while announcing a major strategic shift to unmanned aerial vehicles and a spin-off of its restaurant operations.

Firefly Neuroscience, Inc. reported a 957% revenue increase to $1.142 million in 2025, driven by the Evoke acquisition, but faces substantial doubt about its ability to continue as a going concern due to recurring losses and negative cash flows.